Syntimmune Closes $50 Million Series B Financing led by Apple Tree Partners
Syntimmune, Inc., a clinical-stage biotechnology company focused on FcRn biology, today announced a $50 million Series B financing led by Apple Tree Partners, which has committed $48 million to the round, with additional participation from other existing investors. The funds from the Series B financing will further advance Syntimmune’s clinical development program.
Most Recent Posts:
Innovation Grand Rounds: Investing in your Home-Grown Innovations
Innovation Grand Rounds is a monthly live series with talks by innovators and executives from across the…
Four Brigham Ignite Awards Announced
Innovations focus on CT-guided neurosurgery, knee osteoarthritis, brain tumors, and C-sections BOSTON, MA – September 7,…
Artificial Intelligence Model Outperforms Clinicians in Diagnosing Pediatric Ear Infections
In collaboration with Mass General Brigham Innovation, OtoDx is currently being employed in a prototype device paired…
